Q-omics provides the consensus-scored NPPA profile across patient tissues and cancer cell-line models. NPPA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NPPA is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, NPPA RNA expression shows 16,321 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BRCA, and UVM as cancer lineages where NPPA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPPA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPPA survival associations across molecular data types. NPPA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPPA RNA expression–survival associations across cancer types. High NPPA expression shows unfavorable associations in ACC and KIRC, but favorable associations in LGG, BRCA, PAAD and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NPPA RNA expression.
This table summarizes NPPA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NPPA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPPA shows lower tumor expression in BRCA, LUSC and UCEC and higher tumor expression in COAD, LIHC and ESCA. The BRCA box plot shows higher NPPA RNA expression in normal versus tumor tissue (log2 FC = −0.258, t-test p < 0.001).
This table shows molecular features associated with NPPA in patient tissues and cancer cell lines. In patient samples, NPPA shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPPA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
